Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996

Citation
Sk. Schwarcz et al., Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996, AM J EPIDEM, 152(2), 2000, pp. 178-185
Citations number
69
Categorie Soggetti
Envirnomentale Medicine & Public Health","Medical Research General Topics
Journal title
AMERICAN JOURNAL OF EPIDEMIOLOGY
ISSN journal
00029262 → ACNP
Volume
152
Issue
2
Year of publication
2000
Pages
178 - 185
Database
ISI
SICI code
0002-9262(20000715)152:2<178:IOPIAO>2.0.ZU;2-C
Abstract
The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 15,271 persons in San Francisco, California, diagnosed between 1987 and 1996 with an opportunistic illness included in the 1987 AI DS case definition. Predictors of survival were evaluated for 5,686 persons who were diagnosed between 1993 and 1996 and met the 1993 AIDS case defini tion. Median survival was 19 months for persons diagnosed between 1987 and 1989, 17 months for persons diagnosed between 1990 and 1992, 15 months for persons diagnosed between 1993 and 1994, and 31 months for persons diagnose d between 1995 and 1996. Decreased mortality was associated with use of ant iretroviral therapy without protease inhibitors before AIDS (relative hazar d (RH) = 0.88, 95% confidence interval (CI): 0.8, 1.0) and after AIDS (RH = 0.83, 95% CI: 0.7, 0.9) and use of antiretroviral agents with protease inh ibitors before AIDS (RH = 0.25, 95% CI: 0.2, 0.3) and after AIDS (RH = 0.36 , 95% CI: 0.3, 0.4). Increased mortality was found for persons aged greater than or equal to 40 years (RH = 1.43, 95% CI: 1.3, 1.6), persons initially diagnosed with an opportunistic illness (RH = 1.97, 95% CI: 1.8, 2.2), and homosexual injection drug users (RH = 1.33, 95% CI: 1.2, 1.5). Survival af ter AIDS has increased. Treatment with antiretroviral agents, particularly protease inhibitors, strongly predicts improved survival.